| 1469 |
National Cancer Institute |
Html |
en |
Adult Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of adult central nervous system tumors. |
| type anaplastic astrocytomas | 0.549962 |
| 5-year analysis | 0.459034 |
| rapid immunohistochemical analysis | 0.458442 |
| mutations aids diagnosis | 0.4781 |
| adjuvant temozolomide | 0.53303 |
| BRAF genetic alterations | 0.471994 |
| pontine gliomas | 0.467631 |
| concurrent radiation therapy | 0.474706 |
| MGMT promoter methylation | 0.572789 |
| Radiation Therapy Oncology | 0.484458 |
| oligodendroglial tumors | 0.468432 |
| adult high-grade glioma | 0.464776 |
| Nervous System Tumors | 0.717497 |
| Astrocytic Tumors Treatment | 0.922097 |
| diffuse astrocytomas | 0.480334 |
| prognostic factor | 0.47815 |
| patients | 0.62456 |
| Primary Central Nervous | 0.835704 |
| Tumor Type section | 0.826321 |
| low-grade gliomas | 0.476475 |
| randomized trials | 0.48238 |
| anaplastic gliomas | 0.467716 |
| Treatment Option Overview | 0.469049 |
| standard systemic chemotherapy | 0.485413 |
|
| mutant tumors | 0.500547 |
| malignant gliomas | 0.567609 |
| radiation therapy | 0.833741 |
| standard chemotherapy agent | 0.48857 |
| Lancet Oncol | 0.46722 |
| glioblastoma patients | 0.504986 |
| Radiation Therapy section | 0.489765 |
| deep-seated tumors | 0.489355 |
| Glioblastomas treatment section | 0.511285 |
| diffuse gliomas | 0.494198 |
| CNS tumors | 0.489107 |
| strong prognostic factor | 0.47196 |
| primary malignant glioma | 0.474955 |
| DNA repair enzyme | 0.549791 |
| standard local treatment | 0.596897 |
| Low-grade tumors | 0.493795 |
| oral agent temozolomide | 0.522443 |
| pilocytic astrocytomas | 0.562223 |
| particular glioma subtypes | 0.489447 |
| newly diagnosed glioblastoma | 0.602836 |
| activating point mutation | 0.473461 |
| Tumors Treatment section | 0.972163 |
| mutant-specific IDH1 antibody | 0.464835 |
| potential diagnostic utility | 0.459778 |
|
CLICK HERE |
| 1514 |
National Cancer Institute |
Html |
en |
Colon Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of colon cancer. |
| cancer spreads | 0.373962 |
| malignant tumor cells | 0.372393 |
| body | 0.414717 |
| PDQ cancer information | 0.41292 |
| clinical trial search | 0.41396 |
| stage iii colon | 0.398081 |
| diagnose colon cancer | 0.447265 |
| new blood vessels | 0.38464 |
| clinical trials | 0.682285 |
| nearby lymph nodes | 0.477802 |
| cancer information summary | 0.394223 |
| clinical trial | 0.458525 |
| colorectal cancer | 0.398281 |
| stage ii colon | 0.398385 |
| patients | 0.369754 |
| Local excision | 0.379135 |
| vascular endothelial growth | 0.370513 |
| NCI PDQ cancer | 0.376139 |
| colon cancer cells | 0.445391 |
| radiation therapy | 0.40615 |
| treatment | 0.500834 |
| nonpolyposis colorectal cancer | 0.376908 |
| nearby organs | 0.390945 |
| NCI-supported cancer | 0.38279 |
|
| cancer cells | 0.60536 |
| Cancer Information Service | 0.370496 |
| muscle layer | 0.393193 |
| specific cancer cells | 0.377629 |
| endothelial growth factor | 0.368878 |
| treatment clinical trials | 0.38265 |
| National Cancer Institute | 0.404109 |
| outermost layer | 0.398574 |
| Stage IV colon | 0.386981 |
| new treatment | 0.380079 |
| colon cancer | 0.660263 |
| rectal cancer | 0.382708 |
| metastatic colon cancer | 0.431124 |
| Colon Cancer Treatment | 0.434041 |
| blood | 0.38506 |
| cancer clinical trials | 0.433784 |
| stage | 0.431679 |
| sigmoid colon | 0.383033 |
| cancer information summaries | 0.368601 |
| colon | 0.728312 |
| comprehensive cancer information | 0.368619 |
| cancer | 0.920056 |
| colon wall | 0.603525 |
| Recurrent colon cancer | 0.449006 |
|
CLICK HERE |
| 1516 |
National Cancer Institute |
Html |
en |
Non-Small Cell Lung Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of non-small cell lung cancer. |
| clinical trial | 0.362125 |
| treatment | 0.336369 |
| cancer treatment | 0.206436 |
| chest | 0.203247 |
| Lung Cancer Treatment | 0.202852 |
| clinical trials | 0.52727 |
| external radiation therapy | 0.324228 |
| cancer cells | 0.448727 |
| body | 0.207207 |
| non-small cell lung | 0.914469 |
|
| tyrosine kinase inhibitors | 0.262427 |
| clinical trial search | 0.225847 |
| cancer clinical trials | 0.238028 |
| cell lung cancer | 0.82241 |
| lymph nodes | 0.205659 |
| stage | 0.200928 |
| tumor | 0.257927 |
| radiation therapy | 0.542207 |
| internal radiation therapy | 0.232058 |
| information | 0.22515 |
|
CLICK HERE |
| 1648 |
National Cancer Institute |
Html |
en |
Acupuncture (PDQ®)–Patient Version |
Expert-reviewed information summary about acupuncture as a treatment for people with cancer or cancer-related disorders. |
| sham acupuncture | 0.790117 |
| cancer treatment | 0.64041 |
| real acupuncture | 0.712021 |
| States practice acupuncture | 0.64678 |
| acupuncture practitioner | 0.636806 |
| PDQ cancer information | 0.592449 |
| Microwave acupuncture | 0.620692 |
| clinical trials | 0.757112 |
| acupuncture treatment | 0.66786 |
| cancer information summary | 0.574467 |
| clinical trial | 0.596368 |
| patients | 0.696397 |
| cancer patients | 0.661009 |
| breast cancer survivors | 0.616253 |
| standard care | 0.619139 |
| sham acupuncture group | 0.64456 |
| acupuncture clinical observation | 0.630268 |
| acupuncture needle | 0.654731 |
| acupuncture needles | 0.653493 |
| hot flashes | 0.628474 |
| radiation therapy | 0.576978 |
| real acupuncture works | 0.632379 |
| randomized clinical trials | 0.584867 |
| cancer information | 0.604795 |
| additional acupuncture | 0.614493 |
|
| Acupuncture point injection | 0.633801 |
| United States | 0.574545 |
| Cancer Information Service | 0.583177 |
| Laser acupuncture | 0.622096 |
| acupuncture points | 0.640397 |
| acupuncture point | 0.639768 |
| Auricular acupuncture | 0.62262 |
| studies | 0.661016 |
| National Cancer Institute | 0.633121 |
| sham acupuncture groups | 0.64373 |
| alternative medicine | 0.568566 |
| acupuncture improved xerostomia | 0.627172 |
| pain | 0.585716 |
| therapy | 0.586612 |
| acupuncture practice | 0.611162 |
| acupuncture techniques | 0.624193 |
| breast cancer | 0.617659 |
| traditional Chinese medicine | 0.580302 |
| acupuncture methods | 0.624551 |
| acupuncture method | 0.623018 |
| true acupuncture | 0.617235 |
| acupuncture | 0.900286 |
| Trigger point acupuncture | 0.633788 |
| specific acupuncture point | 0.629179 |
|
CLICK HERE |
| 1673 |
National Cancer Institute |
Html |
en |
Pediatric Supportive Care (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the unique issues that arise for children during their treatment for cancer, after the completion of treatment, and as adult survivors of cancer. |
| cancer treatment | 0.649866 |
| adult cancer survivors | 0.601623 |
| childhood cancers | 0.565975 |
| evidence | 0.583514 |
| newly diagnosed cancer | 0.565444 |
| Dev Behav Pediatr | 0.562444 |
| cancer treatment experience | 0.590476 |
| long-term cancer survivors | 0.591049 |
| childhood cancer survivors | 0.698108 |
| psychological distress | 0.685844 |
| depressive symptoms | 0.576681 |
| childhood brain cancer | 0.596569 |
| children | 0.767093 |
| young adult childhood | 0.567117 |
| healthy children | 0.56615 |
| health-related quality | 0.594398 |
| adolescents | 0.567273 |
| adult survivors | 0.665075 |
| cancer treatment process | 0.592904 |
| suicidal ideation | 0.593505 |
| childhood cancer | 0.981437 |
| cancer survivor study | 0.705202 |
| long-term survivors | 0.62768 |
| parents | 0.589868 |
|
| post-traumatic stress disorder | 0.567933 |
| cancer type | 0.563896 |
| young adult survivors | 0.629083 |
| Brain tumor survivors | 0.559844 |
| cancer experience | 0.564215 |
| Cancer Epidemiol Biomarkers | 0.56534 |
| PUBMED Abstract | 0.593091 |
| posttraumatic stress | 0.563988 |
| Pediatr Blood Cancer | 0.61246 |
| cancer report | 0.558535 |
| similar childhood cancers | 0.564039 |
| FDA Health Advisory | 0.559272 |
| pediatric cancer patients | 0.592812 |
| adult childhood cancer | 0.623021 |
| psychological distress symptoms. | 0.563319 |
| psychological adjustment | 0.574894 |
| Abstract | 0.609735 |
| adult’s cancer | 0.571622 |
| cancer survivorship | 0.563138 |
| childhood cancer survivor | 0.719437 |
| Zebrack BJ | 0.568169 |
| higher levels | 0.659906 |
| major depressive disorder | 0.587361 |
| post-traumatic stress | 0.585398 |
|
CLICK HERE |
| 2007 |
National Cancer Institute |
Html |
es |
Tratamiento de los tumores de células germinativas del sistema nervioso central infantil (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento de los tumores de células germinativas del sistema nervioso central infantil. |
| craniospinal irradiation | 0.316255 |
| germ-cell tumors | 0.313995 |
| intracranial germinoma | 0.409628 |
| cns germ cell | 0.514596 |
| Tumor Study Group | 0.345102 |
| LCR lumbar | 0.316845 |
| germ cell tumours | 0.316685 |
| with chemotherapy | 0.342538 |
| Japanese Pediatric Brain | 0.336647 |
| Patients With Newly | 0.313535 |
| Calaminus G | 0.31314 |
| Radiat Oncol Biol | 0.37391 |
| Pediatric Brain Tumor | 0.404886 |
| Younger Patients With | 0.313094 |
| newly diagnosed cns | 0.31675 |
| nongerminomatous germ cell | 0.322146 |
| central nervous system | 0.442457 |
| with chemotherapy followed | 0.333351 |
| cell tumor study | 0.31798 |
| primary chemotherapy | 0.320021 |
| patients with | 0.448209 |
| radiation therapy | 0.332545 |
| with central nervous | 0.313181 |
| chemotherapy followed | 0.365679 |
| chemotherapy with | 0.323164 |
|
| carcinoma embrionario | 0.318514 |
| nervous system germ | 0.335764 |
| SIOP CNS GCT | 0.316308 |
| Primary intracranial germ | 0.315553 |
| Matsutani M | 0.312979 |
| Neuro Oncol | 0.319601 |
| Pediatr Blood Cancer | 0.338833 |
| system germ cell | 0.348752 |
| focal primary site | 0.31455 |
| Clin Oncol | 0.361515 |
| saco vitelino | 0.314073 |
| sistema nervioso central | 0.472998 |
| Oncol Biol Phys | 0.377556 |
| Brain Tumor Study | 0.347462 |
| Bifocal intracranial germinoma | 0.319163 |
| patients with localized | 0.323174 |
| germ cell tumors | 0.957656 |
| newly diagnosed | 0.329652 |
| treated with | 0.32552 |
| Brain Tumor Consortium | 0.321286 |
| Childs Nerv Syst | 0.319542 |
| Oncology Group | 0.314345 |
| tumor study | 0.348078 |
| primary site irradiation | 0.315366 |
|
CLICK HERE |
| 2109 |
National Cancer Institute |
Html |
es |
Prevención del cáncer de esófago (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre los factores que pueden influir en el riesgo de cáncer de esófago y sobre la investigación dirigida a la prevención de esta enfermedad. |
| siguientes factores | 0.969759 |
| voluntarios sanos | 0.42115 |
| Physician Data Query | 0.489663 |
| Estados Unidos | 0.430297 |
| libre uso | 0.411941 |
| suficiente ejercicio | 0.429799 |
| prevención revisa | 0.420955 |
|
| PDQ Prevención | 0.433383 |
| carcinoma epidermoide | 0.463013 |
| National Cancer Institute | 0.420887 |
| siguientes riesgos | 0.416828 |
| siguientes sumarios | 0.467407 |
| Instituto Nacional | 0.441845 |
|
CLICK HERE |
| 3461 |
National Cancer Institute |
Html |
es |
Temas sobre terapias integrales, alternativas y complementarias (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos de información sobre las terapias integrales, alternativas y complementarias para personas con cáncer. |
| llamada lactobacillus acidophilus | 0.320398 |
| Sun’s Soup | 0.3376 |
| Flor Essence | 0.384105 |
| NCI Best Case | 0.324965 |
| Selected Vegetables | 0.574814 |
| sección suplementos | 0.322686 |
| vitamina d | 0.319364 |
| vitamina c | 0.341075 |
| sustancias quÃmicas llamadas | 0.324421 |
| Unidos Selected Vegetables | 0.324471 |
| Instituto Nacional | 0.442148 |
| sección pectina | 0.32118 |
| Salud Complementaria | 0.335148 |
| pacientes náuseas | 0.357085 |
| coenzima q10 | 0.48743 |
| PDQ Fatiga | 0.398645 |
| Health Interview Survey | 0.325066 |
| Estados Unidos | 0.550173 |
| sección complementos | 0.349035 |
| sección vitamina | 0.346665 |
| cardo mariano | 0.387654 |
| sección intervenciones | 0.319196 |
| punica granatum l | 0.321333 |
| sección intervención | 0.343132 |
| Centro Nacional | 0.320165 |
|
| sección ejercicio | 0.33994 |
| sección soja | 0.320395 |
| sección jengibre | 0.320032 |
| Sun's Soup | 0.379451 |
| sección té | 0.319269 |
| coenzima q10 ayuda | 0.329386 |
| hierba sonajero | 0.430937 |
| pacientes régimen gonzalez | 0.360587 |
| sección granada | 0.318618 |
| PDQ Temas | 0.374069 |
| salud náuseas | 0.319268 |
| pacientes linfedema | 0.359299 |
| San Juan | 0.409901 |
| sección licopeno | 0.323612 |
| sección tratamiento | 0.563476 |
| Physician Data Query | 0.356925 |
| sistema nervioso central | 0.321486 |
| enzimas pancreáticas | 0.337252 |
| cáncer renal | 0.379726 |
| sección terapia | 0.318859 |
| ¿El tratamiento | 0.326217 |
| sección selenio | 0.319463 |
| medicina complementaria | 0.95764 |
| terapia gerson | 0.366138 |
|
CLICK HERE |
| 15479 |
National Cancer Institute |
Html |
en |
Intramural Investigators Submitting Data |
Find general requirements for intramural investigators submitting genomic data. Different processes may exist based on operational differences in NCI intramural research programs. |
| dbGaP staff | 0.612313 |
| Institutional Certification | 0.866347 |
| review process | 0.634188 |
| accession number | 0.623142 |
| accuracy | 0.439647 |
| general requirements | 0.674142 |
| Institutional Review Board | 0.856814 |
| division | 0.480859 |
| Assignment | 0.440982 |
| NCI intramural research | 0.909946 |
| dbGaP Study Release | 0.812896 |
| DSPs | 0.462568 |
| initiation | 0.444589 |
| submission process | 0.630778 |
| Scientific Review | 0.648183 |
| contact | 0.441788 |
| human subjects | 0.63038 |
| studies | 0.475426 |
| required fields | 0.609497 |
| details | 0.440138 |
| expectations | 0.502409 |
| 3. | 0.437685 |
| genomic data | 0.866328 |
|
| DSP | 0.443274 |
| data submission formats | 0.913248 |
| dbGaP submission | 0.646264 |
| study submission information | 0.828375 |
| Basic Study Information | 0.823319 |
| center | 0.480797 |
| operational differences | 0.660458 |
| different processes | 0.658659 |
| steps | 0.441942 |
| QA/QC Data Submission | 0.891139 |
| submission portal | 0.629655 |
| data generation completion | 0.860975 |
| plans | 0.439922 |
| IRB | 0.460706 |
| Data Generation Completed | 0.868892 |
| quality assurance check | 0.803588 |
| GPA | 0.717674 |
| project proposal | 0.64122 |
| programs | 0.443042 |
| time | 0.4353 |
| send | 0.442857 |
| de-identified human specimens | 0.860465 |
|
CLICK HERE |
| 16380 |
National Cancer Institute |
Html |
es |
Toxicidad financiera del tratamiento del cáncer (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del riesgo de sufrir dificultades financieras durante el tratamiento del cáncer. |
| among patients with | 0.356148 |
| National Health Interview | 0.33762 |
| survivors identified through | 0.3506 |
| Guy GP Jr | 0.797953 |
| Targeted Cancer Therapies | 0.346578 |
| seguro médico | 0.502578 |
| Cancer Care Outcomes | 0.395905 |
| Medical Debt And | 0.338028 |
| Care Outcomes Research | 0.337105 |
| cancer care | 0.484521 |
| Adult Cancer Survivors | 0.410356 |
| Ekwueme DU | 0.389597 |
| estudio cancer care | 0.350705 |
| burden among | 0.343127 |
| Health Interview Survey | 0.341695 |
| Blough D | 0.351854 |
| Natl Cancer Inst | 0.34743 |
| cáncer versus | 0.347441 |
| Medicare Current Beneficiary | 0.347647 |
| cancer survivors | 0.793538 |
| Duke Cancer Institute | 0.343096 |
| with cancer | 0.974917 |
| patients with | 0.384813 |
| Medicare beneficiaries with | 0.362941 |
| Dowling EC | 0.336978 |
|
| Hardship Associated With | 0.350445 |
| United States | 0.354013 |
| financial hardship | 0.453927 |
| experiences with cancer | 0.407883 |
| Financial Hardship Associated | 0.350297 |
| Health Aff | 0.447932 |
| Care Cancer | 0.350503 |
| associated with cancer | 0.462553 |
| Debt And Bankruptcy | 0.341472 |
| Yabroff KR | 0.591176 |
| medical expenditure | 0.337994 |
| For Working-Age Cancer | 0.400083 |
| out-of-pocket health care | 0.387866 |
| Working-Age Cancer Survivors | 0.410894 |
| Clin Oncol | 0.748582 |
| breast cancer | 0.503347 |
| Rectal Cancer | 0.343774 |
| Non-elderly Cancer Survivors | 0.355648 |
| cáncer problemas | 0.341283 |
| financial toxicity | 0.423332 |
| patients receiving adjuvant | 0.339287 |
| MEPS Experiences with | 0.352286 |
| Current Beneficiary Survey | 0.336425 |
| expenditure burden | 0.396505 |
|
CLICK HERE |